close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Genmab A/S

< Previous 1 2 3 Next >
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
From Genmab A/S
Via GlobeNewswire
Major Shareholder Announcement
From Genmab A/S
Via GlobeNewswire
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
From Genmab A/S
Via Business Wire
Tickers GMAB
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
Tickers GMAB
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
From Genmab A/S
Via GlobeNewswire
Genmab Announces Changes to its Executive Committee
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Financial Results for the First Half of 2024
From Genmab A/S
Via GlobeNewswire
Genmab Updates 2024 Financial Guidance
From Genmab A/S
Via GlobeNewswire
Genmab Takes Full Control of Acasunlimab Development Program
From Genmab A/S
Via GlobeNewswire
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
Tickers GMAB
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
From Genmab A/S
Via GlobeNewswire
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
Tickers GMAB
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
From Genmab A/S
Via Business Wire
Tickers GMAB
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
From Genmab A/S
Via Business Wire
Tickers GMAB
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From Genmab A/S
Via Business Wire
Tickers BNTX GMAB
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Completes Acquisition of ProfoundBio
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Completes Acquisition of ProfoundBio
From Genmab A/S
Via GlobeNewswire
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Financial Results for the First Quarter of 2024
From Genmab A/S
Via GlobeNewswire
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
Tickers GMAB PFE
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via GlobeNewswire
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
From Genmab A/S
Via GlobeNewswire
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Initiation of Share Buy-Back Program
From Genmab A/S
Via GlobeNewswire
Genmab Publishes 2023 Annual Report
From Genmab A/S
Via GlobeNewswire
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
Tickers GMAB PFE
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
Tickers GMAB PFE
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
Tickers GMAB
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today